



HAL
open science

Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C-ceramide

Susanne Schiffmann, Simone Ziebell, Jessica Sandner, Kerstin Birod, Klaus Deckmann, Daniela Hartmann, Sina Rode, Helmut Schmidt, Carlo Angioni, Gerd Geisslinger, et al.

► To cite this version:

Susanne Schiffmann, Simone Ziebell, Jessica Sandner, Kerstin Birod, Klaus Deckmann, et al.. Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C-ceramide. *Biochemical Pharmacology*, 2010, 80 (11), pp.1632. 10.1016/j.bcp.2010.08.012 . hal-00632284

HAL Id: hal-00632284

<https://hal.science/hal-00632284>

Submitted on 14 Oct 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C_{16:0}-ceramide

Authors: Susanne Schiffmann, Simone Ziebell, Jessica Sandner, Kerstin Birod, Klaus Deckmann, Daniela Hartmann, Sina Rode, Helmut Schmidt, Carlo Angioni, Gerd Geisslinger, Sabine Grösch



PII: S0006-2952(10)00621-0
DOI: doi:10.1016/j.bcp.2010.08.012
Reference: BCP 10691

To appear in: *BCP*

Received date: 28-6-2010
Revised date: 12-8-2010
Accepted date: 13-8-2010

Please cite this article as: Schiffmann S, Ziebell S, Sandner J, Birod K, Deckmann K, Hartmann D, Rode S, Schmidt H, Angioni C, Geisslinger G, Grösch S, Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C_{16:0}-ceramide, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2010.08.012

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Ceramide synthase 6 is activated by celecoxib

1

1
2
3 1 **Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C_{16:0}-**
4
5 2 **ceramide**

6 3 **Running title: Ceramide synthase 6 is activated by celecoxib**

7 3
8 4 **Classification: antibiotics and chemotherapeutics**
9

10 5
11 6
12 6
13
14 7 **Susanne Schiffmann, Simone Ziebell, Jessica Sandner, Kerstin Birod, Klaus Deckmann,**
15
16 8 **Daniela Hartmann, Sina Rode, Helmut Schmidt, Carlo Angioni, Gerd Geisslinger and**
17
18 9 **Sabine Grösch.**

19 10
20 10
21 11
22
23 12 *pharmazentrum frankfurt/ZAFES*, Institut für Klinische Pharmakologie, Klinikum der Goethe-
24
25 13 Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany.

26
27 14 Running head: Ceramide synthase 6 is activated by celecoxib
28
29 15

30 16
31
32 17
33
34 18
35
36 19
37
38 20
39 21
40
41 22
42 23 Corresponding author:
43 24 Susanne Schiffmann, PhD
44 25 Goethe-University/Institute of Clinical Pharmacology
45 26 Theodor-Stern-Kai 7
46 27 60590 Frankfurt/Main,
47 28 Germany
48 29 Phone: +49/69-6301 7820
49 30 Fax: +49/69-6301 7636
50 31 E-mail: susanne.schiffmann@med.uni-frankfurt.de
51 32
52 33
53 34

54 35 key words: cancer, cyclooxygenase-2, (dihydro)ceramide synthase, C_{16:0}-ceramide, celecoxib,
55
56 36 siRNA
57
58
59
60
61
62
63
64
65

ABSTRACT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Ceramides serve as bioactive molecules with important roles in cell proliferation and apoptosis. Ceramides (Cer) with different N-acyl side chains (C_{14:0}-Cer – C_{26:0}-Cer) possess distinctive roles in cell signaling and are differentially expressed in HCT-116 colon cancer cells. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, exhibiting antiproliferative effects, activates the sphingolipid pathway. To elucidate the mechanism, HCT-116 cells were treated with 50 μM celecoxib leading to a significant increase of C_{16:0}-Cer. Interestingly, 50 μM celecoxib resulted in a 2.8 fold increase of ceramide synthase (CerS) activity as measured by a cell-based activity assay. siRNA against several CerSs revealed that CerS6 was predominantly responsible for the increase of C_{16:0}-Cer in HCT-116 cells. Moreover, the silencing of CerS6 partially protected HCT-116 cells from the toxic effects induced by celecoxib. Treatment of cells with celecoxib and fumonisin B1 (inhibitor of CerSs) or myriocin (inhibitor of L-serine palmitoyl transferase) or desipramine (inhibitor of acid sphingomyelinase and acid ceramidase) revealed that the increase of C_{16:0}-Cer results predominantly from activation of the salvage pathway. Using the nude mouse model we demonstrated that celecoxib induces also *in vivo* a significant increase of C_{16:0}-Cer in stomach, small intestine and tumor tissue. In conclusion, celecoxib causes a specific increase of C_{16:0}-Cer by activating CerS6 and the salvage pathway, which contribute to the toxic effects of celecoxib.

Abbreviations: Cer, ceramide; COX-2, cyclooxygenase-2; dhCer, dihydroceramide; CerS, (dihydro)ceramide synthase; DES, dihydroceramide desaturase; FB1, fumonisin B1, GCS, glucosylceramide synthase; KSR, 3-ketosphinganine reductase; Myr, myriocin, SMS, sphingomyelin synthase; SMase, sphingomyelinase; Sph1P, sphingosine-1-phosphate; Sph1PP, sphingosine-1-phosphate phosphatase; dhSph, sphinganine; dhSph1P, sphinganine-1-phosphate; SPT, L-serine palmitoyl transferase.

1. Introduction

As the backbone of several complex sphingolipids (sphingomyelins, glycosylceramides), ceramides are members of the rapidly expanding field of bioactive lipids, which play important roles in the regulation of cell growth, cell differentiation, apoptosis and cell senescence [1]. Briefly, ceramides are synthesized *de novo* from L-serine and palmitoyl-CoA, which are converted subsequently by L-serine palmitoyl transferase (SPT) and 3-ketosphinganine reductase to sphinganine. Acyl-CoAs with chain lengths between C₁₄-C₂₆ are attached to sphinganine by chain length specific (dihydro)ceramide synthases (CerS1-6) [2] to form C₁₄-C₂₆-dihydroceramides. Dihydroceramide desaturase converts these intermediates to C₁₄-C₂₆-ceramides. Sphingosine, produced by the salvage pathway, is also accepted by these CerSs as a substrate, leading to the synthesis of C₁₄-C₂₆-ceramides without the intermediate dihydroceramide (figure 1A). In some tissues such as the testes, ceramides of lengths up to C₃₂ have been detected [3]. As an alternative to *de novo* synthesis, complex sphingolipids may be degraded to ceramides and subsequently to sphingosine in the lysosome as part of the salvage pathway (figure 1A).

The CerS isoforms differ in their substrate specificities and their tissue distribution. Recent publications [4-7] on substrate specificity using cell culture experiments assigned the CerS isoforms to various N-acyl side chains starting with the short chain ceramides as follows: CerS5 (C_{16:0}-Cer, C_{18:0}-Cer, C_{18:1}-Cer); CerS6 (C_{16:0}-Cer, C_{18:0}-Cer); CerS1 (C_{18:0}-Cer); CerS3 (C_{18:0}-Cer, C_{20:0}-Cer); CerS4 (C_{18:0}-Cer, C_{20:0}-Cer, C_{22:0}-Cer, C_{24:0}-Cer); CerS2 (C_{20:0}-Cer, C_{22:0}-Cer, C_{24:0}-Cer). These data indicate a substantial degree of overlap in substrate specificity among the isoforms, obscuring assignment of a specific ceramide to a specific CerS isoform.

1 Ceramides exhibit antiproliferative and proapoptotic effects [8]. Several chemotherapeutics are
2 known to induce apoptosis and/or inhibit cell growth via generation and accumulation of
3 ceramides, either via activation of *de novo* synthesis or through the salvage pathway by the
4 hydrolysis of sphingomyelin by sphingomyelinases (SMase) [9-10]. Which of these pathways are
5 activated depends on the cell type and stimulus (for review see [11]). Interestingly, there are
6 early data suggesting that cancer cells, but not normal cells, are hyper-sensitive to ceramides,
7 thereby raising the sphingolipid pathway as a possible target for cancer therapy [12-13].
8 Celecoxib, a selective COX-2 inhibitor, exhibits pro-apoptotic and growth inhibiting effects in
9 various cancer cells and animal tumor models [14]. It is approved for the adjuvant treatment of
10 familial adenomatous polyposis, an inherited syndrome that predisposes individuals to colon
11 cancer [15]. The antiproliferative activity of celecoxib correlates with inhibition of COX-2 as
12 well as with its ability to inhibit non-COX-2 targets such as 3-phosphoinositide-dependent
13 protein kinase-1 (PDK1), sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) [16]
14 and 5-lipoxygenase [17].
15 A previous study from our group demonstrated that celecoxib influences the sphingolipid
16 pathway by inhibiting dihydroceramide desaturase with an IC₅₀ of 79 μM [18]. In addition to a
17 specific decrease of C_{24:0}-Cer/C_{24:1}-Cer concentration and an increase of dihydroceramide
18 concentration, we also observed an elevation of total ceramide (ceramides and dihydroceramides)
19 levels, which were causatively linked to the apoptotic and growth inhibiting properties of
20 celecoxib. This increase in total ceramide levels after celecoxib treatment cannot exclusively be
21 explained by inhibition of the dihydroceramide desaturase. Therefore, we looked for further
22 targets in the sphingolipid pathway that also could be influenced by celecoxib and thereby
23 contribute to the observed changes in the sphingolipid levels in HCT-116 cells.

2. Experimental

2.1 Cells and reagents

The human cancer cell line HCT-116 was ordered from Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). HCT-116 cells were incubated in McCoy's 5A supplemented with 100 units/ml penicillin G, 100 µg/ml streptomycin, 10% FCS (fetal calf serum) for culturing and 7.5 % FCS in case of treatment. Cells were cultured at 37 °C in an atmosphere containing 5% CO₂. Myriocin, fumonisin B1 and desipramine were purchased from Sigma-Aldrich (Schnelldorf, Germany). siRNAs (CerS2 (s26788), CerS4 (s35896), CerS5 (s40552), CerS6 (s48449)) were purchased from Ambion (Darmstadt, Germany). The sphingolipids and palmitoyl-CoA were purchased either from Avanti Polar Lipids (Alabaster, USA) or Matreya LLC (Pleasant Gap, USA). Celecoxib was synthesized by WITEGA Laboratorien Berlin-Adlershof GmbH. The identity and purity of celecoxib was determined using ¹H-NMR (nuclear magnetic resonance) spectroscopy and high performance liquid chromatography (HPLC) as described previously [19] and was > 99 %.

2.2 Determination of sphingolipid concentrations in cells and in mouse tissue

For the quantification of sphingolipid amounts, cells were seeded at a density of 0.5x10⁶ /5 cm dish and incubated for 24 h. Subsequently, cells were treated with celecoxib in the presence or the absence of 150 nM myriocin and/or 5 µM sphingosine(C₁₇) over various periods of time. The sphingolipids were extracted with methanol as previously described [18]. The mouse tissue was homogenated in PBS and extracted with a mixture of chloroform/methanol (7:1). The extraction and the determination of the sphingolipid concentrations (C_{16:0}-Cer, C_{18:0}-Cer, C_{20:0}-Cer, C_{24:1}-

1 Cer, C_{24:0}-Cer, C_{16:0}-dhCer, C_{24:1}-dhCer, C_{24:0}-dhCer, dhSph, Sph) by liquid chromatography
2 coupled to tandem mass spectrometry (LC-MS/MS) was achieved as published previously [18,
3 20]. Ceramides labeled by the introduction of Sph(C₁₇) exhibit precursor-to-product ion
4 transitions of m/z 496→250 for C_{14:0}-Cer(C₁₇), of m/z 524→250 for C_{16:0}-Cer(C₁₇), of m/z
5 552→250 for C_{18:0}-Cer(C₁₇), of m/z 580→250 for C_{20:0}-Cer(C₁₇), of m/z 608→250 for C_{22:0}-
6 Cer(C₁₇), of m/z 634→250 for C_{24:1}-Cer(C₁₇), of m/z 636→250 for C_{24:0}-Cer(C₁₇), of m/z
7 662→250 for C_{26:0}-Cer(C₁₇), of m/z 552→534 for C_{17:0}-Cer and of m/z 286→268 for Sph(C₁₇),
8 which were used for the Multiple Reaction Monitoring with a dwell time of 15 msec. For
9 analysis, the area under the peak of the analyte was related to the area under the peak of the
10 internal standard. The relative increase of the specific ceramides was calculated using the ratio of
11 analyte to internal standard of untreated cells as the value of 100 %. Data were normalized to the
12 number of treated cells.

15 2.3 Determination of palmitoyl-CoA concentrations in cells

16 For the quantification of palmitoyl-CoA (C_{16:0}-CoA) amounts, cells were seeded at a density of
17 0.5x10⁶, incubated for 24 h and incubated with 50 μM celecoxib for various times. Lipids were
18 extracted with 125 μl acetonitrile/water (50:50, v/v) after the addition of the internal standard
19 (C_{17:0}-CoA). The suspension was sonicated on ice, thoroughly mixed for 1 min and centrifuged
20 for 3 min at 25°C and 20,500 g. The supernatants were collected and the extraction step (no
21 sonication) was repeated with 100 μl acetonitrile/water (50:50, v/v). The amounts of C_{16:0}-CoA
22 and the internal standard were determined by LC-MS/MS. Chromatographic separation was
23 accomplished under gradient conditions using a Gemini C18 column (150 mm x 2 mm ID, 5 μm
24 particle size; Phenomenex, Aschaffenburg, Germany). The HPLC mobile phases consisted of

1
2
3 1 water/ammonium hydroxide (100:0.5, v/v) (A) and acetonitrile/ammonium hydroxide (100:0.5,
4
5 2 v/v) (B). MS/MS analyses were performed on an API 5500 triple quadrupole mass spectrometer
6
7 3 with a Turbo V source (Applied Biosystems, Darmstadt, Germany) in the negative ion mode.
8
9 4 Precursor-to-product ion transitions of m/z 501,7 \rightarrow 78,9 for $C_{16:0}$ -CoA and of m/z 508,6 \rightarrow 78,9
10
11 5 for $C_{17:0}$ -CoA were used for the MRM with a dwell time of 200 msec. Concentrations of the
12
13 6 calibration standards, quality controls and unknowns were evaluated by Analyst software version
14
15 7 1.5 (Applied Biosystems). Linearity of the calibration curve was proven from 1 ng/ml (0.94
16
17 8 pmol/ml) – 100 ng/ml (94 pmol/ml). The coefficient of correlation for all measured sequences
18
19 9 was at least 0.99.
20
21
22
23
24
25
26
27
28
29

30 12 2.4 Determination of mRNA and protein level of CerSs in cells

31
32 13 The mRNA was isolated using an RNA isolation kit (Qiagen, Hilden, Germany) according to the
33
34 14 manufacturer's instructions. cDNA synthesis from 200 ng mRNA was performed using random
35
36 15 hexamers of the verso cDNA Kit (Thermo Scientific, Dreieich, Germany). The expression levels
37
38 16 of CerS1-6 and SPT were determined by TaqmanTM analysis using the SYBR Green Kit
39
40 17 (ABgene Limited, Epsom, United Kingdom) with an ABI Prism 7500 Sequence Detection
41
42 18 System (Applied Biosystems, Austin, USA). Relative expression of SPTLC2 and CerS family
43
44 19 genes was determined using the comparative CT (cycle threshold) method, normalizing relative
45
46 20 values to the expression level of β -actin as a housekeeping gene. The designed primer sets were
47
48 21 published previously [20]. Linearity of the assays was determined by serial dilutions of the
49
50 22 templates for each primer set separately. For western blot analysis the CerS2, CerS6 and HSP90
51
52 23 antibody were purchased from Santa Cruz (Heidelberg, Germany), Sigma Aldrich (Schnelldorf,
53
54 24 Germany) and BD Bioscience (Heidelberg, Germany), respectively. CerS2 and CerS6 antibodies
55
56
57
58
59
60
61
62
63
64
65

1 were diluted 1:200 and incubated over night, while the HSP90 antibody was diluted 1:1000 and
2 incubated for 90 minutes. After washing, the blots were incubated with IRDye 680 conjugated
3 goat anti-rabbit IgG(H+L) or IRDye 800CW conjugated goat anti-mouse IgG(H+L) secondary
4 antibodies purchased from LI-COR (Bad Homburg, Germany). Membranes were analyzed on the
5 Odyssey infrared scanner from LI-COR (Bad Homburg, Germany).

6 7 8 2.5 Silencing of CerS with siRNA

9 2.5×10^5 HCT-116 cells were transfected with 100 pmol CerS2 siRNA/CerS4 siRNA/CerS5
10 siRNA, 150 pmol CerS6 siRNA or 100 pmol scrambled siRNA as control. siPort Amine
11 (Ambion, Darmstadt, Germany) was used for transfection according to the manufacturer`s
12 protocol. Briefly, Opti-MEM medium with transfection reagent were incubated for 10 min at RT,
13 than added to the siRNA solution consisting of Opti-MEM medium and siRNA, followed by an
14 incubation for 10 min at RT. 2.5×10^5 HCT-116 cells were incubated with siRNA transfection
15 solution, and the process was repeated after 24h. After 41h the transfected HCT-116 cells were
16 either harvested for mRNA isolation (RNA isolation kit (Qiagen, Hilden, Germany)) or treated
17 with DMSO or 50 μ M celecoxib and subjected to sphingolipid analysis. The effectiveness of the
18 siRNA knock-down was verified using quantitative PCR.

19 20 21 2.6 Nude mice experiment

22 In a previous study we demonstrated that celecoxib exhibit also *in vivo* its antiproliferative
23 effects using the nude mouse model [21]. For the current study brain, heart, lung, liver, small
24 intestine, large intestine, kidney, testes and tumor tissue from these mice were extracted and

1 washed with 0.9 % saline and frozen by -80°C . In all experiments, the ethics guidelines for
2 investigations in conscious animals were obeyed and the local Ethics Committee for Animal
3 Research approved the experiments.

2.7 In vitro cell viability assay

4
5
6
7 The WST-1 assay (Roche Diagnostic GmbH, Mannheim) was used to determine the viability and
8 proliferation rate of the cells after treatment with CerS6 siRNA and celecoxib or DMSO. The
9 cells were treated with 62.5 nMol CerS6 siRNA or 62.5 nMol scrambled siRNA for 41h.
10 Subsequently, the cells were treated either with 50 μM celecoxib or DMSO. After 20h of
11 incubation 10 μl of WST-1 reagent were added to each well and the cells were incubated for
12 further 90 min. The formation of the dye was measured at 450 nm against a reference wavelength
13 of 620 nm using a 96-well spectrophotometric plate reader (SPECTRAFlour Plus, Tecan,
14 Crailsheim, Germany). For the calculation of the cell viability the DMSO treated cells were used
15 as the 100% value.

2.8 Statistics

16
17
18 Ceramide levels, palmitoyl-CoA levels and mRNA expression data are presented as a mean \pm
19 s.e.m (standard error of the mean). Ceramide data and mRNA expression data of the cell culture
20 experiments were analyzed using an independent t-test and the confidence interval was set at
21 95%. Ceramide data of the nude mice experiments were analyzed using an independent t-test and
22 the confidence interval was set at 95%, while the variances were assumed as not equal. The SPSS
23 9.01 software was used for statistical analyses.

3. Results

3.1 Time dependent alteration of ceramide levels in HCT-116 cells after treatment with celecoxib

We recently published that celecoxib inhibits the (dihydro)ceramide desaturase causing an increase of C_{16:0}-, C_{24:1}-, C_{24:0}-dihydroceramide and a decrease of C_{24:1}- and C_{24:0}-ceramide. Interestingly, the amount of C_{16:0}-ceramide remained unaltered in that study after 2 h of celecoxib (80 μ M) treatment. However, the total ceramide level (includes C_{16:0}-, C_{24:1}-, C_{24:0}-dihydroceramide and ceramides) doubled relative to the control [18]. In this former study, we investigated shorter time periods with higher celecoxib concentrations (80 μ M) since celecoxib exhibits an IC₅₀ value of 79 \pm 2 μ M for the (dihydro)ceramide desaturase. For the present study, a concentration of 50 μ M celecoxib was applied to minimize the influence of (dihydro)ceramide desaturase inhibition by celecoxib. Since the present study focused on the mechanism of sphingolipid pathway induction by celecoxib, HCT-116 cells were treated in a time dependent fashion up to 20 h with 50 μ M celecoxib or DMSO (vehicle control). Ceramide concentrations were determined by LC-MS/MS. The treatment of HCT-116 cells with celecoxib time-dependently and significantly increased the amounts of C_{16:0}-dhCer, C_{24:1}-dhCer, C_{24:0}-dhCer, sphinganine and sphingosine as well as C_{14:0}-Cer, C_{16:0}-Cer and C_{18:0}-Cer (figure 1B, data are only partly shown). Instead, the ceramides C_{20:0}-, C_{24:1}- and C_{24:0}-ceramide decreased time-dependently (figure 1B). All in all, the total ceramide levels (including dihydroceramides (C_{16:0}-C_{24:0}), ceramides (C_{14:0}-C_{24:0}), sphingosine, sphinganine) increased by up to 210 \pm 30 % after incubation with 50 μ M celecoxib for 6 h as compared to cells treated with DMSO.

1 3.2 mRNA and protein expression of CerSs and SPT in HCT-116 cells after celecoxib treatment

2
3 1 The observed increase of $C_{14:0}$ -Cer, $C_{16:0}$ -Cer and $C_{18:0}$ -Cer could may be a consequence of
4
5 2 The observed increase of $C_{14:0}$ -Cer, $C_{16:0}$ -Cer and $C_{18:0}$ -Cer could may be a consequence of
6
7 3 induction of the key enzymes of the sphingolipid pathway CerSs and/or SPT (figure 1A).
8
9

10 4 Therefore, we analyzed the expression level of CerSs and SPT by quantitative real time PCR and
11
12 5 by western blot analysis. In HCT-116 cells, CerS2 may be the predominant isoform while CerS4,
13
14

15 6 CerS5 and CerS6 are six fold less expressed (figure 2A). Experimentally, the expression level of
16
17 7 CerS1 and CerS3 was below the limit of detection (data not shown). HCT-116 cells were
18
19

20 8 incubated either with 50 μ M celecoxib or with DMSO (control) for the indicated time periods.
21

22 9 Our data exhibit that the mRNA expression of CerS2, which is specific for the synthesis of
23
24 10 longer ceramides like $C_{24:1}$ - and $C_{24:0}$ -Cer (see figure 5B, and [4]), significantly increased after
25
26

27 11 celecoxib treatment whereas the expression levels of CerS4, CerS5 didn't change. mRNA levels
28
29 12 of CerS6 and SPTLC2 slightly but significantly increased after 4h and decreased after 16h of
30
31

32 13 treatment with celecoxib as compared to the respective control. These results are unexpected due
33
34 14 to literature reports [4] and our own CerS6 knock down experiments (see figure 5B) indicating
35
36

37 15 that CerS6 is specific for the synthesis of short ceramides like $C_{16:0}$ -Cer. Since the mRNA levels
38
39 16 of CerS2 and CerS6 are slightly increased after celecoxib treatment, we checked the influence of
40
41

42 17 celecoxib on protein levels of CerS2 and CerS6. HCT-116 cells were time dependently incubated
43
44 18 with 50 μ M celecoxib or with DMSO (control). As shown in figure 2B celecoxib has no
45
46

47 19 influence on the protein amounts of CerS2 or CerS6.
48
49 20

50

51 21

52
53
54 22 3.3 Ceramide synthase activity

55
56 23 As the increase of $C_{16:0}$ -Cer after celecoxib treatment was most pronounced we focused in the
57
58 24 following on this ceramide species. Our RNA and protein data suppose that the increase in $C_{16:0}$ -
59
60
61
62
63
64
65

1 Cer is not to be due to an upregulation of CerS6, therefore we investigated the ability of
2 celecoxib to activate CerSs. Unfortunately, an activity assay using the microsomal fraction of
3 HCT-116 cells showed no activation of CerSs by celecoxib treatment [18]. The same
4 experiments also revealed that inhibition of the (dihydro)ceramide desaturase after celecoxib
5 treatment was only detectable in living cells. Therefore, we developed a cell-based assay to
6 detect the influence of celecoxib on ceramide synthase activity. In this assay, exogenously added
7 sphingosine(C₁₇) functioned as substrate that is transformed to ceramides(C₁₇) by the action of
8 the various ceramide synthases. The usage of sphingosine effectively excludes the participation
9 of (dihydro)ceramide desaturase, which is responsible for the generation of ceramide from
10 dihydroceramide if sphinganine (dihydro-sphingosine) is the substrate (see figure 1A). With the
11 use of sphingosine(C₁₇), leading to the formation of ceramide(C₁₇), we could discriminate
12 between endogenous ceramide(C₁₈) and the newly synthesized ceramide(C₁₇). Furthermore,
13 HCT-116 cells were incubated with 150 nM myriocin, an inhibitor of the SPT, to block the
14 endogenous sphinganine synthesis to reduce the natural substrate of the CerSs [18]. Inhibition of
15 SPT does not influence the amounts of palmitoyl-CoA, a precursor of *de novo* sphingolipid
16 synthesis (data not shown). HCT-116 cells were either incubated for 2 h with DMSO/5 μM
17 sphingosine(C₁₇)/150 nM myriocin (control) or with 50 μM celecoxib/5 μM
18 sphingosine(C₁₇)/150 nM myriocin (figure 3A). Following the incubation, sphingolipids were
19 extracted and measured by LC-MS/MS. The levels of the different ceramide(C₁₇) species in
20 control cells were set at 100%. The amounts of ceramide(C₁₇) species in cells treated with
21 celecoxib were scaled to the control levels. Celecoxib treatment led to an increase of C_{16:0}-
22 Cer(C₁₇) by 280%, and of C_{14:0}-Cer(C₁₇) by 123%, while the other ceramides (C_{18:0}-Cer(C₁₇),
23 C_{20:0}-Cer(C₁₇), C_{22:0}-Cer(C₁₇), C_{24:1}-Cer(C₁₇), C_{24:0}-Cer(C₁₇), C_{26:0}-Cer(C₁₇)) decreased. The

1
2
3 1 increase of C_{16:0}-Cer occurs time dependently and starts after treatment of cells with celecoxib
4
5 2 for 2 h (figure 3 B).
6
7
8 3
9
10 4

12 5 3.4 Celecoxib did not increase the palmitoyl-CoA level

15 6 Palmitoyl-CoA, in addition to sphingosine, is essential for the synthesis of C_{16:0}-Cer by the
16
17 7 (dihydro)ceramide synthase. Addition of exogenous palmitoyl-CoA predominantly led to an
18
19
20 8 increase of C_{16:0}-Cer (data not shown). To investigate whether or not celecoxib treatment leads to
21
22 9 an increase of palmitoyl-CoA, which could in turn activate the (dihydro)ceramide synthase, we
23
24
25 10 measured the amount of palmitoyl-CoA in celecoxib treated HCT-116 cells using LC-MS/MS.
26
27 11 As shown in figure 4, palmitoyl-CoA amounts time-dependently decreased within 2 h. The
28
29
30 12 decrease was more pronounced in cells treated with 50 μ M celecoxib than in control cells. The
31
32 13 decrease of palmitoyl-CoA in untreated and celecoxib treated cells could be due to an increase of
33
34
35 14 ceramides (data not shown) induced either by celecoxib (see above) or by growth activation due
36
37 15 to growth factors in fresh media.
38
39
40 16
41
42 17
43

44 18 3.5 Ceramide synthase 6 is involved in C_{16:0}-Cer synthesis in HCT-116 cells

46
47 19 Subsequently, we addressed the question whether or not celecoxib activates a specific CerS in
48
49 20 HCT-116 cells. Therefore, we performed silencing experiments using siRNA for CerS2, CerS4,
50
51 21 CerS5, and CerS6. HCT-116 cells were either untreated (control) or treated with scrambled
52
53
54 22 siRNA, or the respective siRNAs for the various CerSs for 41 h. The mRNA expression was
55
56
57 23 determined using relative quantitative PCR. The mRNA expression of the various CerSs was
58
59 24 normalized to GAPDH and scaled to untreated cells. Scrambled siRNA (unspecific siRNA) led

1 to a slight increase of the expression of all ceramide synthases as compared to untreated cells
2
3 (figure 5A). The mRNA expression of CerS2, CerS4, CerS5 and CerS6 were reduced to 13%,
4
5 25%, 32%, 27%, respectively, by their specific siRNAs (figure 5A). The various siRNAs were
6
7 specific, as demonstrated by the lack of significant cross regulation to other CerSs (data not
8
9 shown). Furthermore, none of the various siRNAs altered the mRNA expression of β -Actin
10
11 which was used as control (figure 5A). These results confirm the specificity of the CerS siRNAs
12
13 to down-regulate their specific endogenous targets. To determine whether or not decreased
14
15 mRNA expression levels affect the ceramide levels, we measured the ceramide levels after 41 h
16
17 treatment with the various siRNAs. Silencing of CerS2 decreased the synthesis of $C_{24:1}$ -Cer/ $C_{24:0}$ -
18
19 Cer, silencing of CerS4 slightly decreased the synthesis of $C_{16:0}$ -Cer/ $C_{24:1}$ -Cer/ $C_{24:0}$ -Cer and
20
21 silencing of CerS6 significantly decreased the synthesis of $C_{16:0}$ -Cer. Silencing of CerS5 had no
22
23 effect on the predominantly synthesized ceramides (figure 5B). These data indicate that CerS6 is
24
25 predominantly responsible for the synthesis of $C_{16:0}$ -Cer. Therefore, we investigated, whether or
26
27 not silencing of CerS6 by siRNA could also prevent the induction of $C_{16:0}$ -Cer production in
28
29 HCT-116 cells after celecoxib treatment. HCT-116 cells were pretreated with siRNA against
30
31 CerS6. Afterwards, the cells were incubated with 150 nM myriocin, to inhibit sphingolipid de
32
33 novo synthesis, and with DMSO/5 μ M sphingosine(C_{17}) or 50 μ M celecoxib/5 μ M
34
35 sphingosine(C_{17}) for 2h. Treatment of cells with siRNA against CerS6 completely prevented the
36
37 celecoxib induced increase of $C_{16:0}$ -Cer(C_{17}) in HCT-116 cells (figure 5C). In contrast, CerS2,
38
39 CerS4 and CerS5 silencing in HCT-116 cells exhibited only a slight decrease in $C_{16:0}$ -Cer(C_{17})
40
41 synthesis induced by celecoxib. In conclusion both the cell based activity assay as well as the
42
43 ceramide expression pattern after silencing various CerSs points to CerS6 as a target of
44
45 celecoxib.

1
2
3 1
4
5 2 3.6 Celecoxib activates the salvage pathway
6
7
8 3 Ceramides are either synthesized via a salvage pathway or *de novo* synthesis. Since ceramide
9
10 4 synthases play an essential role in both pathways, we investigated which pathway is activated by
11
12 5 celecoxib. For this purpose, an inhibitor of the L-serine palmitoyl transferase (myriocin) was
13
14
15 6 used, which only blocks the *de novo* synthesis. In contrast, the non-selective ceramide synthase
16
17 7 inhibitor fumonisin B1 (FB1) blocks both the salvage pathway and the *de novo* synthesis of
18
19
20 8 ceramides. HCT-116 cells were incubated with either DMSO (control), 50 μ M celecoxib, 70 μ M
21
22 9 FB1, 150 nM myriocin or co-treated with a mixture of 50 μ M celecoxib/70 μ M FB1 or 50 μ M
23
24 10 celecoxib/150 nM myriocin for 6 h. In Fig. 6A we were able to show that myriocin alone reduces
25
26
27 11 the C_{16:0}-Cer levels below the control levels (dark grey bar). In comparison, treatment of cells
28
29
30 12 with 50 μ M celecoxib and myriocin (striped, dark grey bar) reduces the ceramide levels
31
32 13 approximately to control (white bar), but as compared to the myriocin treated cells (dark grey
33
34 14 bar), the inhibition is not complete. Instead, fumonisin B1 inhibits ceramide production nearly to
35
36
37 15 the same extent in control cells as well as in celecoxib treated cells. The difference in C_{16:0}-Cer
38
39 16 levels between celecoxib/fumonisin B1 treated cells and cells treated with celecoxib/myriocin
40
41 17 may be due to the ceramide synthesized by the salvage pathway. Desipramine induces the
42
43
44 18 degradation of the acid sphingomyelinase and the down-regulation of acid ceramidase [22]
45
46
47 19 leading to a partial inhibition of the salvage pathway (figure 1A). HCT-116 cells were incubated
48
49 20 with either DMSO (control), 50 μ M celecoxib, 20 μ M desipramine or co-treated with a mixture
50
51 21 of 50 μ M celecoxib/20 μ M desipramine 6 h. Fig 6C shows that treatment of control cells with
52
53
54 22 desipramine alone has only a slight effect on C_{16:0}-Cer levels, indicating that the
55
56
57 23 sphingomyelinase pathway plays only a minor role for the synthesis of C_{16:0}-Cer in control cells.
58
59 24 In contrast, desipramine completely prevents the increase of ceramide induced by celecoxib
60
61
62
63
64
65

1 treatment. These data point out that after celecoxib treatment the de novo synthesis plays only a
2 minor role for the production of C_{16:0}-Cer whereas the salvage pathway seems to have a more
3 important role. Treatment of HCT-116 cells with celecoxib significantly increased the amount of
4 sphingosine, which is a key precursor of the salvage pathway (see figure 1A, figure 6B). 20 µM
5 desipramine reduced the sphingosine level in control cells and completely prevented an increase
6 of sphingosine after celecoxib treatment (Fig 6B). These data indicate that celecoxib treatment
7 lead to an activation of the salvage pathway in HCT-116 cells.

3.7 Celecoxib specifically increases C_{16:0}-Cer in nude mice tissue

8
9
10 In order to support the results obtained *in vitro*, nude mice were used to generate *in vivo* data. We
11 demonstrated in a previous study that celecoxib inhibits the tumor growth of HCT-116
12 xenografts in nude mice [21]. Nude mice were treated for three weeks with 10 mg/kg celecoxib
13 or with vehicle. For further analysis, the brain, lung, heart, stomach, large intestine, small
14 intestine, testes and the tumor tissues were extracted. The tissues were homogenized and the
15 sphingolipids were extracted and determined by LC-MS/MS. In line with the *in vitro* data,
16 celecoxib treatment significantly increased the level of C_{16:0}-Cer in stomach, small intestine and
17 tumor tissue of the nude mice (figure 7). No differences were detectable in the other tissues
18 investigated. Interestingly, no changes were observed after celecoxib treatment for C_{24:1}-Cer and
19 C_{24:0}-Cer.

3.8 Silencing of CerS6 protects cells against the anti-proliferative effect of celecoxib

1 Next we checked, whether the increased C_{16:0}-Cer level could be at least in part responsible for
2 the observed toxic effects of celecoxib. For this purpose we silenced the CerS6 expression
3 transiently in HCT-116 cells and compared the toxic effects of celecoxib with control HCT-116
4 cells. Treatment of HCT-116 cells with 50 µM celecoxib for 24h reduced the viability of control
5 cells about 24 % and only about 8% in CerS6 silenced cells (figure 8). These data indicate that
6 activation of CerS6 and therefore an increase in C_{16:0}Cer is important for the toxic effect of
7 celecoxib.

10 4. Discussion

13 Investigations about the “specialization” of ceramides, especially their specific synthesis and
14 their sophisticated role in cell regulation are currently a hot topic of research. To date, few
15 reports describe the differential regulation of ceramides with various chain-lengths. As data
16 accumulate, it is becoming increasingly apparent that the chain length, subcellular location and
17 the biosynthetic pathway (salvage or *de novo*) of ceramides all contribute to physiological and
18 pathophysiological regulatory mechanisms in the cell [11]. Moreover, there are various proteins
19 that can recognize ceramides with a high degree of fatty acid chain length specificity, such as the
20 ceramide transport protein CERT (preference for C_{16:0}-Cer/ C_{18:0}-Cer) [23] and the inhibitor 2 of
21 protein phosphatase2A (preference for C_{18:0}-Cer) [24].

22 Celecoxib induces a significant increase of C_{16:0}-Cer *in vitro* in HCT-116 colon carcinoma cells
23 as well as *in vivo* in nude mouse tissues, the stomach, the small intestine and tumor tissues. This
24 elevation was attributed to an elevated enzymatic activity of CerS6 and not to transcriptional

1 upregulation of CerS6. In another study we could show that only the overexpression of CerS6 in
2
3 HCT-116 cells led to an increase of C_{16:0}-Cer (unpublished data). Furthermore, we demonstrated
4
5 that celecoxib activates predominantly the salvage pathway, as inhibition of the *de novo*
6
7 synthesis by L-serine palmitoyl transferase inhibitor only slightly prevents the increase of C_{16:0}-
8
9 Cer amounts, while inhibition of CerSs by fumonisin B1 blocks more effectively the increase of
10
11 C_{16:0}-Cer amounts. Apart from inhibiting N-acylation of sphinganine, which occurs downstream
12
13 of the SPT, fumonisin B1 also blocks the reacylation of sphingosine produced by the salvage
14
15 pathway (see also figure 1A). Nevertheless, both, the increase of the mRNA level of SPT and of
16
17 sphinganine followed by treatment with celecoxib as well as the effectiveness of myriocin
18
19 suggest that also the *de novo* synthesis is involved. Interestingly, the endocannabinoid analog
20
21 R(+)-methanandamide increased the ceramide level in neuroglioma cells by activating the
22
23 ceramide synthases of the salvage pathway but not of *de novo* synthesis, since the ceramide
24
25 upregulation was prevented by fumonisin B1 but not by myriocin [25]. Furthermore,
26
27 desipramine, blocking the degradation of sphingomyelin to ceramide by aSMase, which is one
28
29 resource of sphingosine, completely prevented the increase of sphingosine and C_{16:0}-Cer after
30
31 celecoxib treatment.

32
33 In a previous study we could show that myriocin prevents, at least partially, celecoxib-induced
34
35 growth inhibition as well as apoptosis [18]. With the data presented here, we could demonstrate
36
37 that the salvage pathway and CerS6 are targets of celecoxib. Silencing of CerS6 significantly
38
39 reduced celecoxib-induced growth-inhibition (figure 8), suggesting that specific activation of this
40
41 ceramide synthase and thereby accumulation of C_{16:0}-Cer contributes to the toxic effects of
42
43 celecoxib. The role of C_{16:0}-Cer and other ceramides in cancer development are actually highly
44
45 debated. In this regard White-Gilbertson et al. reported that TRAIL-(tumor necrosis factor-
46
47 related apoptosis-inducing ligand-) induced apoptosis depends on activation of CerS6 and
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 synthesis of C_{16:0}-Cer [26]. Moreover, irradiation treatment of Molt-4 leukemia cells led to a p53
2
3 dependent synthesis of C_{16:0}-Cer through a transcriptional upregulation of CerS5 [27].
4
5 Furthermore not only the increase or decrease of one specific ceramide could be involved in
6
7 tumor development but also an altered ratio of the ceramides. Liu et al. [28] postulated that the
8
9 altered ratio of C_{16:0}-Cer/C_{24:0}-Cer is responsible for the induction of apoptosis. The observation
10
11 that an increase in the ratio of C_{16:0}-Cer/C_{24:0}-Cer from 1.28 in untreated cells to 3.09 in
12
13 celecoxib-treated (50 μ M, 6 h) cells supports the notion that the ratio C_{16:0}-Cer/C_{24:0}-Cer is
14
15 critical.
16
17

18
19 But our data raises another important question: how does celecoxib selectively activate one
20
21 specific ceramide synthase? Ceramide synthases are located at the endoplasmic reticulum, where
22
23 the *de novo* synthesis occurs [29] and at mitochondria-associated membranes [30]. However,
24
25 whether these enzymes are also involved in *de novo* synthesis or whether they only play a role in
26
27 the salvage pathway is not clear. Interestingly, a previous study revealed that during cerebral
28
29 ischemia/reperfusion mitochondrial ceramide levels are elevated due to the activation of
30
31 mitochondrial ceramide synthases by post-translational mechanisms [31]. Interestingly, in mouse
32
33 brain only CerS1, CerS2 and CerS6 are located in the mitochondrial membrane, while CerS5 is
34
35 located in the endoplasmic reticulum [31]. Such specific localizations could be the rationale for
36
37 the specific activation of CerS6 in HCT-116 cells by celecoxib. The activation of CerS6 after
38
39 celecoxib treatment is only observable in living cells with intact membrane structures. Recently,
40
41 we showed that celecoxib accumulates specifically in cellular membranes [32]. This
42
43 accumulation of celecoxib may explain why we only observed an activation of CerS6 in viable
44
45 cells. Furthermore, activation of an enzyme may depend on post-translational modifications as
46
47 well as co-factor and substrate availability. An increase in substrate availability could be
48
49 excluded in these experiments, because celecoxib does not raise the palmitoyl-CoA
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 concentration. Beside of a direct mechanism, several possibilities for an indirect activation exist:

2 1) *Alterations in the quaternary structure of the CerSs*. Koyanagi et al. linked already augmented
3 levels of dihydroceramide and ceramide in tumor tissue to CerSs with a larger than normal
4 molecular mass [33]. 2) *Translocation processes of the CerSs*. Cisplatin induces rapid
5 translocation of CerS1 but not CerS4 or CerS5 from ER to Golgi apparatus [7]. 3)
6 *Phosphorylation of the CerSs*. Using the SWISS_Prot data bank we found several potential
7 phosphorylation sides in the CerS6 protein sequence. But whether one of these mechanisms
8 contributes to the effect observed after celecoxib treatment requires further investigations.

9 In conclusion, our data clearly demonstrate that celecoxib activates CerS6 and thereby causes an
10 increase of C_{16:0}-Cer level, which, in turn, contributes to the toxic effects of celecoxib. The
11 influence of celecoxib on the sphingolipid pathway might be of great clinical relevance. On the
12 one hand celecoxib is used in clinical trials for cancer treatment regimes. On the other hand
13 celecoxib is investigated for usability against Alzheimer disease [34]. Progression of this disease
14 is positively correlated with ceramide levels [35].

17 ACKNOWLEDGEMENTS

18
19
20 The authors thank Dr. Wesley McGinn-Straub for the linguistic revision of the manuscript. This
21 work was supported by the Deutsche Forschungsgemeinschaft (DFG) Forschergruppe FOG 784 /
22 TP5 (GR2011/2-1) and the LOEWE Lipid Signaling Forschungszentrum Frankfurt (LiFF).

25 REFERENCES

1. Ogretmen B and Hannun YA, Biologically active sphingolipids in cancer pathogenesis and treatment. *Nat Rev Cancer* **4**(8): 604-16, 2004.
2. Pewzner-Jung Y, Ben-Dor S and Futerman AH, When do Lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. *J Biol Chem* **281**(35): 25001-5, 2006.
3. Rabionet M, van der Spoel AC, Chuang CC, von Tumpling-Radosta B, Litjens M, Bouwmeester D, Hellbusch CC, Korner C, Wiegandt H, Gorgas K, Platt FM, Grone HJ and Sandhoff R, Male germ cells require polyenoic sphingolipids with complex glycosylation for completion of meiosis: a link to ceramide synthase-3. *J Biol Chem* **283**(19): 13357-69, 2008.
4. Mizutani Y, Kihara A and Igarashi Y, Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. *Biochem J* **390**(Pt 1): 263-71, 2005.
5. Riebeling C, Allegood JC, Wang E, Merrill AH, Jr. and Futerman AH, Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. *J Biol Chem* **278**(44): 43452-9, 2003.
6. Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill AH, Jr. and Futerman AH, Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. *J Biol Chem* **283**(9): 5677-84, 2008.
7. Min J, Mesika A, Sivaguru M, Van Veldhoven PP, Alexander H, Futerman AH and Alexander S, (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. *Mol Cancer Res* **5**(8): 801-12, 2007.
8. Ruvolo PP, Intracellular signal transduction pathways activated by ceramide and its metabolites. *Pharmacol Res* **47**(5): 383-92, 2003.
9. Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ and Hannun YA, Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. *J Biol Chem* **275**(12): 9078-84, 2000.
10. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE and Cabot MC, Taxol-induced ceramide generation and apoptosis in human breast cancer cells. *Cancer Chemother Pharmacol* **47**(5): 444-50, 2001.
11. Modrak DE, Gold DV and Goldenberg DM, Sphingolipid targets in cancer therapy. *Mol Cancer Ther* **5**(2): 200-8, 2006.
12. Guenther GG, Peralta ER, Rosales KR, Wong SY, Siskind LJ and Edinger AL, Ceramide starves cells to death by downregulating nutrient transporter proteins. *Proc Natl Acad Sci U S A* **105**(45): 17402-7, 2008.
13. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA and Clavien PA, Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. *Cancer Res* **61**(3): 1233-40, 2001.
14. Koki AT and Masferrer JL, Celecoxib: a specific COX-2 inhibitor with anticancer properties. *Cancer Control* **9**(2 Suppl): 28-35, 2002.
15. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B, The effect of celecoxib, a

- 1
2
3 1 cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* **342**(26):
4 2 1946-52, 2000.
- 5 3 16. Grosch S, Maier TJ, Schiffmann S and Geisslinger G, Cyclooxygenase-2 (COX-2)-
6 4 independent anticarcinogenic effects of selective COX-2 inhibitors. *J Natl Cancer Inst*
7 5 **98**(11): 736-47, 2006.
- 8 6 17. Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C, Metzner J, Groesch S,
9 7 Pergola C, Steinhilber D, Werz O and Geisslinger G, Celecoxib inhibits 5-lipoxygenase.
10 8 *Biochem Pharmacol* **76**(7): 862-72, 2008.
- 11 9 18. Schiffmann S, Sandner J, Schmidt R, Birod K, Wobst I, Schmidt H, Angioni C,
12 10 Geisslinger G and Grosch S, The selective COX-2 inhibitor celecoxib modulates
13 11 sphingolipid synthesis. *J Lipid Res* **50**(1): 32-40, 2009.
- 14 12 19. Brautigam L, Vetter G, Tegeder I, Heinkele G and Geisslinger G, Determination of
15 13 celecoxib in human plasma and rat microdialysis samples by liquid chromatography
16 14 tandem mass spectrometry. *J Chromatogr B Biomed Sci Appl* **761**(2): 203-12., 2001.
- 17 15 20. Schiffmann S, Sandner J, Birod K, Wobst I, Angioni C, Ruckhaberle E, Kaufmann M,
18 16 Ackermann H, Lotsch J, Schmidt H, Geisslinger G and Grosch S, Ceramide synthases
19 17 and ceramide levels are increased in breast cancer tissue. *Carcinogenesis* **30**(5): 745-52,
20 18 2009.
- 21 19 21. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger
22 20 G and Grosch S, The anti-proliferative potency of celecoxib is not a class effect of coxibs.
23 21 *Biochem Pharmacol* **76**(2): 179-87, 2008.
- 24 22 22. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, Mahdy A, Zeidan
25 23 Y, Bielwaska A, Hannun YA and Norris JS, New insights on the use of desipramine as an
26 24 inhibitor for acid ceramidase. *FEBS Lett* **580**(19): 4751-6, 2006.
- 27 25 23. Kudo N, Kumagai K, Tomishige N, Yamaji T, Wakatsuki S, Nishijima M, Hanada K and
28 26 Kato R, Structural basis for specific lipid recognition by CERT responsible for
29 27 nonvesicular trafficking of ceramide. *Proc Natl Acad Sci U S A* **105**(2): 488-93, 2008.
- 30 28 24. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF,
31 29 Arnold HK, Sears RC, Hannun YA and Ogretmen B, Direct interaction between the
32 30 inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of
33 31 protein phosphatase 2A activity and signaling. *Faseb J*, 2008.
- 34 32 25. Ramer R, Weinzierl U, Schwind B, Brune K and Hinz B, Ceramide is involved in r(+)-
35 33 methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. *Mol*
36 34 *Pharmacol* **64**(5): 1189-98, 2003.
- 37 35 26. White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L and Voelkel-
38 36 Johnson C, Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation
39 37 of active caspase-3 in colon cancer cells. *Oncogene* **28**(8): 1132-41, 2009.
- 40 38 27. Panjarian S, Kozhaya L, Arayssi S, Yehia M, Bielawski J, Bielawska A, Usta J, Hannun
41 39 YA, Obeid LM and Dbaibo GS, De novo N-palmitoylsphingosine synthesis is the major
42 40 biochemical mechanism of ceramide accumulation following p53 up-regulation.
43 41 *Prostaglandins Other Lipid Mediat* **86**(1-4): 41-8, 2008.
- 44 42 28. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, Bielawski J, Dong
45 43 JY, El-Zawahry AM, Guo GW, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Keane
46 44 TE, Tavassoli M and Norris JS, Acid ceramidase inhibition: a novel target for cancer
47 45 therapy. *Front Biosci* **13**: 2293-8, 2008.
- 48 46 29. Futerman AH and Riezman H, The ins and outs of sphingolipid synthesis. *Trends Cell*
49 47 *Biol* **15**(6): 312-8, 2005.

- 1
2
3 1 30. Bionda C, Portoukalian J, Schmitt D, Rodriguez-Lafrasse C and Ardail D, Subcellular
4 2 compartmentalization of ceramide metabolism: MAM (mitochondria-associated
5 3 membrane) and/or mitochondria? *Biochem J* **382**(Pt 2): 527-33, 2004.
6 4 31. Yu J, Novgorodov SA, Chudakova D, Zhu H, Bielawska A, Bielawski J, Obeid LM,
7 5 Kindy MS and Gudz TI, JNK3 signaling pathway activates ceramide synthase leading to
8 6 mitochondrial dysfunction. *J Biol Chem* **282**(35): 25940-9, 2007.
9 7 32. Maier TJ, Schiffmann S, Wobst I, Birod K, Angioni C, Hoffmann M, Lopez JJ, Glaubitz
10 8 C, Steinhilber D, Geisslinger G and Grosch S, Cellular membranes function as a storage
11 9 compartment for celecoxib. *J Mol Med*, 2009.
12 10 33. Koyanagi S, Kuga M, Soeda S, Hosoda Y, Yokomatsu T, Takechi H, Akiyama T,
13 11 Shibuya S and Shimeno H, Elevation of de novo ceramide synthesis in tumor masses and
14 12 the role of microsomal dihydroceramide synthase. *Int J Cancer* **105**(1): 1-6, 2003.
15 13 34. Group AR, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S
16 14 and Sabbagh M, Naproxen and celecoxib do not prevent AD in early results from a
17 15 randomized controlled trial. *Neurology* **68**(21): 1800-8, 2007.
18 16 35. Katsel P, Li C and Haroutunian V, Gene expression alterations in the sphingolipid
19 17 metabolism pathways during progression of dementia and Alzheimer's disease: a shift
20 18 toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?
21 19 *Neurochem Res* **32**(4-5): 845-56, 2007.
22 20
23 21
24 22
25 23
26 24
27 25
28 26
29 27
30 28
31 29
32 30
33 31
34 32
35 33
36 34
37 35
38 36
39 37
40 38
41 39
42 40
43 41
44 42
45 43
46 44
47 45
48 46
49 47
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

LEGENDS

Fig. 1A. Scheme of the sphingolipid *de novo* synthesis and the salvage pathway. SPT, L-serine palmitoyltransferase; Myr, myriocin; CerS, (dihydro)ceramide synthase; FB1, fumonisin B1; SMase, sphingomyelinase, Des, desipramine. B) Time-dependent alteration of the sphingolipid level in HCT-116 cells treated with celecoxib. The cells were treated for various time points (2h, 6h, 8h, 16h, 20h) with 50 μ M celecoxib (light blue) or with DMSO (control, dark blue). The ceramide levels were determined with LC-MS/MS and normalized to the number of treated cells. Data are mean \pm s. e. m. of two independent experiments each achieved in triplicate. * ($p < 0.05$) $^{\circ}$ ($p < 0.01$) $^{+}$ ($p < 0.001$) indicate significant difference between celecoxib and DMSO treated cells at the various time points.

Fig. 2. The time-dependent effect of celecoxib both on the mRNA expression level and on the protein level of ceramide synthases. HCT-116 cells were treated for various time points as indicated with 50 μ M celecoxib or with DMSO (control). A) The relative mRNA expression of CerS2, CerS4, CerS5, CerS6 and SPTLC2 were normalized to β -actin. The relative mRNA levels were calculated with respect to control cells at the same time point. Data are mean \pm s. e. m. of one of two comparable independent experiments, each achieved in duplicate. B) Western blot analysis of CerS2 and CerS6. As internal standard the heat shock protein HSP90 was used (one of two independent experiments is shown).

Fig. 3. Cell based ceramide synthase activity assay. HCT-116 cells were preincubated 90 min with 150 nM myriocin and then co-treated either with 50 μ M celecoxib/5 μ M sphingosine(C₁₇)/150 nM myriocin or with DMSO/5 μ M sphingosine(C₁₇)/150 nM myriocin (control) for 2 h (A) or various time points (B). The amounts of ceramide(C17) were determined by LC-MS/MS. For analysis the area under the peak of the analyte was related to the area under the peak of the internal standard. The relative increase of the specific ceramides was calculated using the ratio analyte to internal standard of untreated cells as 100% value. The ceramide ratios were normalized to the number of treated cells. Data are mean \pm s. e. m. of one of three comparable independent experiments each achieved in duplicate.

Fig. 4. Celecoxib treatment reduces the palmitoyl-CoA level in HCT-116 cells. HCT-116 cells were treated either with DMSO (white bars) or with 50 μ M celecoxib (black bars) for the indicated time points. The palmitoyl-CoA levels were determined with LC-MS/MS and normalized to the number of treated cells. Data are mean \pm s. e. m. of one of two comparable independent experiments each achieved in triplicate. * ($p < 0.05$) ** ($p < 0.01$) indicate significant difference between celecoxib or DMSO treated cells at various time points and untreated cells (time point 0h).

Fig. 5. Silencing of CerSs in HCT-116 cells using specific siRNAs. A) mRNA level in siRNA treated HCT-116 cells. The cells were incubated 41 h with CerS2, CerS4, CerS5, CerS6 or scrambled siRNA. The mRNA expression of CerS2, CerS4, CerS5 and CerS6 were normalized to GAPDH. The relative mRNA expressions of the CerSs were calculated using cells treated only

1 with transfection reagent as 100 % value. As an additional control for the specificity of the
2
3 siRNA treatment we checked the mRNA expression of β -actin. As a representative experiment
4
5 the mRNA expression of β -actin after treatment with CerS4 siRNA is indicated. Data are mean \pm
6
7 s. e. m. of three independent experiments each achieved in triplicate. B) Ceramide levels in
8
9 siRNA (scrambled, CerS2, CerS4, CerS5, CerS6) treated HCT-116 cells. The ceramide levels
10
11 were determined using LC-MS/MS and were normalized to the number of treated cells. The
12
13 relative ceramide level was calculated using the ceramide level of HCT-116 cells treated with
14
15 scrambled siRNA as 100% value. Data are mean \pm s. e. m. of two independent experiments each
16
17 achieved in duplicate. ** ($p < 0.01$) and * ($p < 0.05$) indicate significant difference between CerS
18
19 siRNA treated and scrambled siRNA treated cells. C) Activity assay in siRNA treated HCT-116
20
21 cells. After 41 h treatment with siRNA (against CerS2, CerS4, CerS5, CerS6 or scrambled) HCT-
22
23 116 cells were preincubated 90 min with 150 nM myriocin and subsequently co-incubated with
24
25 50 μ M celecoxib/5 μ M sphingosine(C_{17})/150 nM myriocin or with DMSO/5 μ M
26
27 sphingosine(C_{17})/150 nM myriocin (control) for 2h. The amounts of ceramide(C_{17}) were
28
29 determined by LC-MS/MS. For analysis the area under the peak of the analyte was related to the
30
31 area under the peak of the internal standard. The relative increase of the specific ceramides was
32
33 calculated using the ratio analyte to internal standard of DMSO-treated cells as 100% value. The
34
35 ceramide ratios were normalized to the number of treated cells. Data are mean \pm s. e. m. of one of
36
37 three comparable independent experiments each achieved in duplicate. *** ($p < 0.001$) indicate
38
39 significant difference between celecoxib treated and control cells.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **Fig. 6.** A) $C_{16:0}$ -Cer level in HCT-116 cells after treatment with celecoxib and inhibitors of the de
57
58 novo synthesis or salvage pathway. HCT-116 cells were preincubated (90 min) with 70 μ M FB1,
59
60
61
62
63
64
65

1 150 nM myriocin or DMSO and subsequently treated with DMSO (control), 50 μ M celecoxib, 70
2 μ M FB1, 50 μ M celecoxib/70 μ M FB1, 150 nM myriocin, 150 nM myriocin/50 μ M celecoxib
3 for 6h. B/C) The sphingosine (B) and C_{16:0}-Cer (C) level in HCT-116 cells after treatment with
4 celecoxib and desipramine. HCT-116 cells were preincubated (90 min) with 20 μ M desipramine
5 or DMSO and subsequently treated with DMSO (control), 50 μ M celecoxib, 20 μ M desipramine
6 and 50 μ M celecoxib/20 μ M desipramine for 6h. The C_{16:0}-Cer and sphingosine levels
7 determined with LC-MS/MS were normalized to the number of treated cells. Data are mean \pm s.
8 e. m. of two independent experiments each achieved in duplicate. A significant increase of C_{16:0}-
9 Cer and sphingosine as indicated are marked with an asterisk (*p < 0.05, ***p < 0.001).
10 Abbreviations: Cel, celecoxib; FB1, fumonisin B1; Myr, myriocin, Desip, desipramine.


11
12
13 **Fig. 7.** Effects of orally administered celecoxib on the C_{16:0}-Cer (A), C_{24:1}-Cer (B) and C_{24:0}-Cer
14 (C) ceramide level in mouse tissue. Approximately 1×10^7 HCT-116 tumor cells were injected
15 subcutaneously into the left and right dorsal flank of nude mice. Mice received either vehicle or
16 10 mg/kg celecoxib daily. Treatment started 4 days post implantation. After three weeks the mice
17 were sacrificed, the tissues (brain, heart, lung, liver, stomach (stom.), kidney, small intestine (s.
18 int.), large intestine (l. int.), testis, tumor) were extracted, washed with 0.9 % saline and the
19 amount of ceramides were determined using LC-MS/MS. A significant increase of ceramide
20 amount in celecoxib-treated mice versus untreated control mice is indicated with an asterisk (*p
21 < 0.05, ***p < 0.001).

1 **Fig. 8.** Effect of CerS6 silencing on celecoxib-induced cell toxicity. HCT-116 cells were
2
3 pretreated with 62.5 nMol CerS6 siRNA or with 62.5 nMol scrambled siRNA (control) for 41h
4
5 and subsequently treated either with 50 μ M celecoxib or with DMSO for 20h. Cell viability was
6
7 determined using the WST-1 proliferation assay. Data are mean \pm s. e. m. of one of three
8
9 comparable independent experiments each achieved in duplicate. * ($p < 0.01$) indicate significant
10
11 difference between scrambled siRNA and CerS6 siRNA treated cells.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1

A)

Figure 1



B)






Figure 2


Figure 2



B)



A)



B)




Figure 4

□ Control
■ 50 μ M Celecoxib

A)




Figure 5

Figure 5






Figure 6

A)





Figure 6



B)



C)






Figure 7

A)



B)



C)






Figure 8





Treatment of cancer cells with celecoxib led to a significant increase of C_{16:0}-Cer via the specific activation of ceramide synthase 6 (CerS6). The increase in C_{16:0}-Cer contributes in part to the proapoptotic effect of celecoxib.

Figure for reviewer II




Figure: Densitometric analyses of western blot of CerS2 (Figure 2A)